FDA approves Roche’s Tecentriq in combination with Avastin for people with the most common form of liver cancer
Tecentriq in combination with Avastin is the first and only cancer immunotherapy regimen approved for the treatment of unresectable or metastatic hepatocellular carcinoma.
Read more